In the setting of late presentation (CD4 cell count <200 cell/mm3 or AIDS), a recent study conducted in Cina showed a high 48-week virological effectiveness comparable to our study with 93.8% (122/130) of the patients who achieved HIV-RNA levels <50 copies/ml without any TAF/FTC/BIC treatment discontinuation [22]. The gene discussed is CD4; the disease is AIDS.